Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohn's Disease

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Jan 26

PMID 23349929

Citations 44

Authors

Francesca Zorzi

Ivan Monteleone

Massimiliano Sarra

Emma Calabrese

Irene Marafini

Micaela Cretella

Silvia Sedda

Livia Biancone

Francesco Pallone

Giovanni Monteleone

Affiliations

Soon will be listed here.

Abstract

Objective: Crohn's Disease (CD)-associated inflammation is supposed to be driven by T helper (Th)1/Th17 cell-derived cytokines, even though there is evidence that the mucosal profile of cytokine may vary with the evolution of the disease. We aimed at comparing the pattern of effector cytokines in early and established lesions of CD.

Design: Mucosal samples were taken from the neo-terminal ileum of CD patients undergoing ileocolonic resection, with (early lesions) or without post-operative recurrence, and terminal ileum of CD patients with long-standing disease undergoing intestinal resection (established lesions). Inflammatory cell infiltrate was examined by immunofluorescence and cytokine expression was analysed by real-time PCR, flow-cytometry and ELISA.

Results: Before the appearance of endoscopic lesions, the mucosa of the neo-terminal ileum contained high number of T cells and macrophages, elevated levels of Th1-related cytokines and TNF-α and slightly increased IL-17A expression. Transition from this stage to endoscopic recurrence was marked by abundance of Th1 cytokines, marked increase in IL-17A, and induction of IL-6 and IL-23, two cytokines involved in the control of Th17 cell responses. In samples with established lesions, there was a mixed Th1/Th17 response with no TNF-α induction. Expression of IL-4 and IL-5 was up-regulated in both early and established lesions even though the fraction of IL-4-producing cells was lower than that of cells producing either interferon-γ or IL-17A.

Conclusions: Distinct mucosal profiles of cytokines are produced during the different phases of CD. A better understanding of the cytokines temporally regulated in CD tissue could help optimize therapeutic interventions in CD.

Citing Articles

Immunohistochemistry Analysis in Inflammatory Bowel Disease-Should We Bring to Light Interleukin-10?.

Pavel C, Diculescu M, Ilie M, Plotogea O, Sandru V, Enache V Biomedicines. 2025; 13(2).

PMID: 40002819 PMC: 11853417. DOI: 10.3390/biomedicines13020406.

Comparing the Effects of Anti-TNF Agent and Ustekinumab on Small Bowel Inflammation in Crohn's Disease: Inverse Probability Weighting With Stabilized Weights of Propensity Scores.

Hirata Y, Nishioka D, Nishida K, Shimizu H, Mizuta N, Numa K Crohns Colitis 360. 2024; 6(2):otae033.

PMID: 38864024 PMC: 11165431. DOI: 10.1093/crocol/otae033.

Management of Post-Operative Crohn's Disease: Knowns and Unknowns.

Spertino M, Gabbiadini R, Dal Buono A, Busacca A, Franchellucci G, Migliorisi G J Clin Med. 2024; 13(8).

PMID: 38673573 PMC: 11051270. DOI: 10.3390/jcm13082300.

CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease.

Gomez-Bris R, Saez A, Herrero-Fernandez B, Rius C, Sanchez-Martinez H, Gonzalez-Granado J Int J Mol Sci. 2023; 24(3).

PMID: 36769019 PMC: 9916759. DOI: 10.3390/ijms24032696.

A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes.

Estevinho M, Moreira P, Silva I, Laranjeira Correia J, Santiago M, Magro F Therap Adv Gastroenterol. 2022; 15:17562848221142673.

PMID: 36569381 PMC: 9772959. DOI: 10.1177/17562848221142673.

References

Renna S, Camma C, Modesto I, Cabibbo G, Scimeca D, Civitavecchia G . Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology. 2008; 135(5):1500-9. DOI: 10.1053/j.gastro.2008.07.066. View

Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F . Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997; 112(4):1169-78. DOI: 10.1016/s0016-5085(97)70128-8. View

McLeod R, Wolff B, Steinhart A, Carryer P, ORourke K, ANDREWS D . Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology. 1997; 113(6):1823-7. DOI: 10.1016/s0016-5085(97)70001-5. View

Kugathasan S, Saubermann L, Smith L, Kou D, Itoh J, Binion D . Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut. 2007; 56(12):1696-705. PMC: 2095703. DOI: 10.1136/gut.2006.116467. View

Sarra M, Pallone F, Macdonald T, Monteleone G . IL-23/IL-17 axis in IBD. Inflamm Bowel Dis. 2010; 16(10):1808-13. DOI: 10.1002/ibd.21248. View

Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O . Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology. 1997; 113(1):118-26. DOI: 10.1016/s0016-5085(97)70116-1. View

Reinisch W, Hommes D, Van Assche G, Colombel J, Gendre J, Oldenburg B . A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut. 2006; 55(8):1138-44. PMC: 1856289. DOI: 10.1136/gut.2005.079434. View

Kaser A, Zeissig S, Blumberg R . Inflammatory bowel disease. Annu Rev Immunol. 2010; 28:573-621. PMC: 4620040. DOI: 10.1146/annurev-immunol-030409-101225. View

Regueiro M, Schraut W, Baidoo L, Kip K, Sepulveda A, Pesci M . Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2008; 136(2):441-50.e1. DOI: 10.1053/j.gastro.2008.10.051. View

10.

Biank V, Broeckel U, Kugathasan S . Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm Bowel Dis. 2007; 13(11):1430-8. DOI: 10.1002/ibd.20213. View

11.

Neurath M, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H . The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med. 2002; 195(9):1129-43. PMC: 2193714. DOI: 10.1084/jem.20011956. View

12.

Ouyang W, Kolls J, Zheng Y . The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008; 28(4):454-67. PMC: 3424508. DOI: 10.1016/j.immuni.2008.03.004. View

13.

Schmitt N, Morita R, Bourdery L, Bentebibel S, Zurawski S, Banchereau J . Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity. 2009; 31(1):158-69. PMC: 2731623. DOI: 10.1016/j.immuni.2009.04.016. View

14.

Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Iuliano R . Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol. 1999; 163(1):143-7. View

15.

Monteleone G, Caprioli F . T-cell-directed therapies in inflammatory bowel diseases. Clin Sci (Lond). 2010; 118(12):707-15. DOI: 10.1042/CS20100027. View

16.

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

17.

Spencer D, Veldman G, Banerjee S, Willis J, Levine A . Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology. 2002; 122(1):94-105. DOI: 10.1053/gast.2002.30308. View

18.

Monteleone G, Parrello T, Luzza F, Pallone F . Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7. Gut. 1998; 43(5):620-8. PMC: 1727325. DOI: 10.1136/gut.43.5.620. View

19.

Strober W, Fuss I, Mannon P . The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007; 117(3):514-21. PMC: 1804356. DOI: 10.1172/JCI30587. View

20.

Fuss I, Neurath M, Boirivant M, Klein J, de La Motte C, Strong S . Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996; 157(3):1261-70. View